Peptide Selank OXY-SELA (10 mg) OxyPharma

Catalogue entry: Peptide Selank OXY-SELA (10 mg) OxyPharma. Labelled content: 10 mg. Listed pack: 1 vial. The amount identifies labelled product content, not an administration dose.

Identity and mechanism

Selank is a synthetic heptapeptide related to the tuftsin sequence, with research into anxiety-related and neurobiological effects. It is distinct from Semax, an ACTH-fragment-derived peptide. Similar placement in a cognition or wellbeing category does not establish a shared mechanism or equivalent evidence.

What the research measured

Zozulia and colleagues reported a comparison with medazepam in patients with anxiety and neurasthenia in 2008. Medvedev and colleagues later described another anxiety-related clinical comparison. These studies concern particular patient groups and methods. They do not demonstrate improved concentration, decision-making under sporting pressure or competitive performance in healthy consumers.

Sporting claims and limitations

A claim of reduced anxiety must be assessed separately from sedation, function and long-term safety. Publication of small clinical observations does not resolve all adverse effects or establish suitability for a different formulation. Regulatory compounding assessments have highlighted insufficient human safety information and peptide-related immunogenicity concerns. Those limitations should not be replaced by a broad natural-or-selective reassurance.

Product identity and documentation

For this catalogue item, verify the full peptide name, chemical form and actual batch. Presentation and product formulation matter when comparing research, rather than simply assuming that the same name means the same exposure. Analytical identity and quality tests should match the supplied lot. The selected labelled amount is product information, not a mental-health treatment instruction or a sporting-use protocol.